Company Performance Metrics
- Arnoud Dijkstra: Chief Business Officer
Jeffrey Lawson: Chief Scientific Officer
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable of
immediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.
These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
